A5024680185- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Genetic factors in colorectal cancer
- Gene expression and cancer classification
- Colorectal Cancer Treatments and Studies
- Ubiquitin and proteasome pathways
- Bioinformatics and Genomic Networks
- Molecular Biology Techniques and Applications
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- RNA Research and Splicing
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Cancer-related molecular mechanisms research
- Radiomics and Machine Learning in Medical Imaging
- Effects and risks of endocrine disrupting chemicals
- Extracellular vesicles in disease
- Gastric Cancer Management and Outcomes
- Ovarian cancer diagnosis and treatment
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- PARP inhibition in cancer therapy
Natera (United States)
2021-2025
Icahn School of Medicine at Mount Sinai
2015-2021
Russian Cancer Research Center NN Blokhin
2011-2017
VIB-KU Leuven Center for Cancer Biology
2016
KU Leuven
2016
Centre international de recherche sur le cancer
2013
Institut Curie
2009-2012
Inserm
2009-2012
Martin Luther University Halle-Wittenberg
2009
Hybrigenics (France)
2009
Abstract Deregulation of the ubiquitin/proteasome system has been implicated in pathogenesis many human diseases, including cancer. Ubiquitin-specific proteases (USP) are cysteine involved deubiquitination protein substrates. Functional connections between USP7 and essential viral proteins oncogenic pathways, such as p53/Mdm2 phosphatidylinositol 3-kinase/protein kinase B networks, strongly suggest that targeting with small-molecule inhibitors may be useful for treatment cancers diseases....
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an observational arm the ongoing CIRCULATE-Japan study (UMIN000039205) that analyzed presurgical ctDNA in stage II-IV CRC (n = 1,039). In this cohort, a median follow-up 16.74 months (range 0.49-24.83...
Abstract Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (g / 2 )-mutant advanced breast cancer, but its activity beyond g poorly understood. We conducted Talazoparib Beyond BRCA ( NCT02401347 ), an open-label phase II trial, to evaluate talazoparib patients with pretreated HER2-negative cancer n = 13) or other solid tumors 7) mutations homologous recombination (HR) pathway genes than . In four had Response Evaluation Criteria Solid Tumors (RECIST) partial response...
The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated association circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC). This updated a 23-month median follow-up, including 2,240 patients stage II-III colon or IV CRC, reinforces prognostic value ctDNA positivity during MRD window significantly inferior disease-free survival (DFS;...
9 Background: ctDNA-based post-surgical detection of molecular residual disease (MRD) is known to be predictive a high risk recurrence. Here, we report the first results BESPOKE CRC, multicenter, prospective, observational study evaluating ability tumor-informed ctDNA assay inform ACT treatment decisions in stage II/III CRC patients (pts). Methods: Of 1792 pts enrolled between 2020-07-02 and 2022-08-25, plasma samples from 350 with II-III were analyzed. was detected quantified using...
PURPOSE This study aimed to assess (1) the prognostic value of circulating tumor DNA (ctDNA) and (2) ability ctDNA detect recurrence compared with standard surveillance in curatively resected early-stage biliary tract cancer (BTC). METHODS retrospective, multicenter cohort evaluated serial testing for patients BTC after curative resection. We relapse-free survival (RFS) by positivity. The sensitivity detecting a confirmed BTC, defined as biopsy-proven or true progression radiographic...
Lung cancer is the major human malignancy, accounting for 30% of all cancer-related deaths worldwide. Poor survival lung patients, together with late diagnosis and resistance to classic chemotherapy, highlights need identification new biomarkers early detection. Among different biomarkers, small non-coding RNAs called microRNAs (miRNAs) are considered most promising, owing their remarkable stability, cancer-type specificity, presence in body fluids. However, results multiple previous...
Research Article8 February 2016Open Access Source DataTransparent process OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination Maria Francesca Baietti Center for the Biology of Disease, VIB, Leuven, Belgium Human Genetics, KU Search more papers this author Michal Simicek Layka Abbasi Asbagh Enrico Radaelli Sam Lievens Department Medical Protein Research, Biochemistry, Gent University, Gent, Jonathan Crowther Mikhail Steklov Vasily N Aushev Institute Carcinogenesis,...
Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA esophagogastric cancers (EGC) is less characterized could identify high-risk who have been curative intent.In this retrospective analysis real-world data, levels were analyzed the preoperative, postoperative, surveillance settings EGC using a personalized multiplex polymerase chain reaction-based next-generation sequencing assay. Plasma...
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. We examined utility of circulating tumor DNA (ctDNA) as a prognostic biomarker for EOC by assessing its relationship with patient outcome and CA-125, pre-surgically during post-treatment surveillance.
Abstract Introduction Personalized and tumor-informed circulating tumor DNA (ctDNA) testing is feasible allows for molecular residual disease (MRD) identification in patients with pancreatic ductal adenocarcinoma (PDAC). Methods In this retrospective analysis of commercial cases from multiple US institutions, personalized, tumor-informed, whole-exome sequenced, germline-controlled ctDNA levels were quantified analyzed PDAC. Plasma samples (n = 1329) 298 clinically validated collected at...
15 Background: BESPOKE CRC, a multicenter, prospective, observational study investigated the clinical utility of ctDNA for detecting MRD-based early recurrence in pts with surgically resected CRC. The primary endpoint was to assess impact testing on treatment decisions and asymptomatic rates. secondary MRD clearance rate, survival MRD-negative pts, overall survival, patient-reported outcomes. Methods: Complete laboratory data were available 1001 stages II–III Longitudinal performed...
Immune checkpoint inhibitors have shown great promise in treating patients with mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) colorectal cancer (CRC). Although single-agent pembrolizumab has been approved for first-line treatment of dMMR/MSI-H metastatic CRC, combination therapy cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) inhibition (ipilimumab/nivolumab) reported higher response rates. It is unclear whether who progress on PD-1 will respond to CTLA-4...
5 Background: A growing body of evidence supports the utility circulating tumor DNA (ctDNA) as a useful biomarker for detecting molecular residual disease (MRD) in colorectal cancer (CRC). Immediately after surgery or during adjuvant therapy, high levels cell-free (cfDNA) from normal tissue may limit detection tumor-derived ctDNA. The optimal timing blood collection reliable MRD therapy remains unclear. Methods: In this retrospective, U.S.-based, multi-institutional study, data commercial...
6 Background: Our previous analysis of data from the prospective, observational GALAXY study (UMIN000039205) reported post surgical detection molecular residual disease (MRD) to be prognostic patient (pt) outcomes and most significant risk factor for recurrence regardless BRAF V600E status. Here, we present an updated correlation ctDNA dynamics with in pts radically resected, stage II-IV CRC study. Methods: A personalized, tumor-informed assay (Signatera, Natera, Inc.) was used...
MicroRNAs (miRNAs) are small regulatory non-coding RNAs with a diversity of cellular functions, and frequently dysregulated in cancer. Using novel computational method (ActMir) that we recently developed, the "activity" miRNA hsa-miR-500a was implicated estrogen receptor (ER) positive breast cancer; however its targets functional impact remain poorly understood. Here, performed an extensive gene expression analysis ER+ cancer cell lines, to reveal miR-500a-5p after experimental modulation...
Abstract Background: Gynecological cancers are a diverse set of malignancies, each with distinct genomic alterations that influence tumorigenesis and disease progression. Here, we analyzed data from endometrial, ovarian, cervical cancer patients, stratified by genetic ancestry, to assess differences in mutational landscapes. Methods: Whole-exome sequencing (WES) >8, 000 gynecological cases Natera’s proprietary Real-World Database were utilized. WES was performed on tumor tissues for...
Abstract Background: Colorectal cancer (CRC) is a heterogeneous disease driven by multitude of genomic alterations that influence tumor progression and clinical outcomes. Genomic profiling plays crucial role in identifying actionable mutations understanding the molecular drivers CRC. In this study, we analyzed data from Natera’s proprietary Real-World Database, comprising more than 100, 000 CRC patients, to characterize mutational landscape investigate patterns across subgroups. Methods: We...
Several studies have demonstrated the prognostic value of circulating tumor DNA (ctDNA); however, correlation mean molecules (MTM)/ml plasma and variant allele frequency (mVAF; %) with clinical parameters is yet to be understood. In this study, we analyzed ctDNA data in a pan-cancer cohort 23 543 patients who had testing performed using personalized, tumor-informed assay (Signatera™, mPCR-NGS assay). For ctDNA-positive patients, between MTM/ml mVAF was examined. Two subanalyses were...